<code id='2930387509'></code><style id='2930387509'></style>
    • <acronym id='2930387509'></acronym>
      <center id='2930387509'><center id='2930387509'><tfoot id='2930387509'></tfoot></center><abbr id='2930387509'><dir id='2930387509'><tfoot id='2930387509'></tfoot><noframes id='2930387509'>

    • <optgroup id='2930387509'><strike id='2930387509'><sup id='2930387509'></sup></strike><code id='2930387509'></code></optgroup>
        1. <b id='2930387509'><label id='2930387509'><select id='2930387509'><dt id='2930387509'><span id='2930387509'></span></dt></select></label></b><u id='2930387509'></u>
          <i id='2930387509'><strike id='2930387509'><tt id='2930387509'><pre id='2930387509'></pre></tt></strike></i>

          Home / Wikipedia / explore

          explore


          explore

          author:entertainment    Page View:71825
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In